Literature DB >> 9527797

In vitro activities of Y-688, a new 7-substituted fluoroquinolone, against anaerobic bacteria.

A P MacGowan1, K E Bowker, M Wootton, H A Holt, D S Reeves.   

Abstract

The in vitro activities of Y-688, a new 7-substituted fluoroquinolone derivative, against 317 nonduplicate anaerobic isolates were determined. Eighty-five percent of the Bacteroides fragilis group (n = 89) were inhibited by < or = 2 mg of Y-688 per liter, while 78, 100, 89, and 98% of gram-negative bacilli (n = 135), gram-positive cocci (n = 59), and non-spore-forming (n = 58) and spore-forming (n = 51) gram-positive bacilli, respectively, were inhibited by < or = 1 mg of Y-688 per liter.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9527797      PMCID: PMC105425          DOI: 10.1128/AAC.42.2.419

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  The laboratory identification of gram-positive anaerobic cocci.

Authors:  D A Murdoch; I J Mitchelmore
Journal:  J Med Microbiol       Date:  1991-05       Impact factor: 2.472

2.  The in-vitro activity of trovafloxacin and nine other antimicrobials against 413 anaerobic bacteria.

Authors:  K E Bowker; M Wootton; H A Holt; D S Reeves; A P MacGowan
Journal:  J Antimicrob Chemother       Date:  1996-08       Impact factor: 5.790

3.  In vitro activity of the new quinolone BAY y 3118 against anaerobic bacteria.

Authors:  C E Nord; A Lindmark; I Persson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-08       Impact factor: 3.267

4.  A simple and sensitive technique for determining and fermentation reactions of non-sporing anaerobes.

Authors:  K D Phillips
Journal:  J Appl Bacteriol       Date:  1976-10

5.  The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents.

Authors:  J Child; J Andrews; F Boswell; N Brenwald; R Wise
Journal:  J Antimicrob Chemother       Date:  1995-06       Impact factor: 5.790

6.  Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

7.  Comparative activities of eight quinolones against members of the Bacteroides fragilis group.

Authors:  M V Borobio; M Conejo; E Ramirez; A I Suarez; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

8.  Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria.

Authors:  E J Goldstein; D M Citron
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

9.  In vitro activity of DU-6859a against anaerobic bacteria.

Authors:  H M Wexler; E Molitoris; D Reeves; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

10.  In-vitro activity of clinafloxacin (CI-960) and PD 131628-2 against anaerobic bacteria.

Authors:  H M Wexler; E Molitoris; D Reeves; S M Finegold
Journal:  J Antimicrob Chemother       Date:  1994-10       Impact factor: 5.790

  10 in total
  2 in total

Review 1.  Meropenem: an updated review of its use in the management of intra-abdominal infections.

Authors:  M N Lowe; H M Lamb
Journal:  Drugs       Date:  2000-09       Impact factor: 9.546

Review 2.  Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.

Authors:  H D Langtry; H M Lamb
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.